Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPV With and Without Enoxaparin for Rhegmatogenous Retinal Detachment
NCT07787377Active, not recruiting
- Sponsor
- Lahore General Hospital
- Start
- May 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Randomised trial of enoxaparin in rhegmatogenous retinal detachment (RRD) and Proliferative Vitreoretinopathy (PVR) (2 arms), sponsored by Lahore General Hospital. Primary endpoint: Postoperative Visual Acuity at 3 months. Started May 2026; status: active, not recruiting.
02
Drugs
enoxaparin
03
Conditions
rhegmatogenous retinal detachment (RRD)Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT07787377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787377.